In 2017, diabetes continued to pull in the profits for the key players in the metabolic disorders market, representing 66% of total metabolic sales.

The top five companies in the metabolic space mainly attribute their success to the sales of their anti-diabetic drugs. This is unsurprising as the number of US patients diagnosed with diabetes breached 32 million in 2017.

Novo Nordisk is currently the world leader in the diabetes market and will remain so for years to come. The company boasted sales of $13.7 million in 2017. Sanofi/Regeneron and Amgen will further strengthen their position in the metabolic disorders space with their expected blockbusters Praluent and Repatha, despite initial slow uptake in 2017.

Currently, 15 out of 20 top-selling drugs in the metabolic disorders space are anti-diabetics. With Sanofi’s Lantus and Merck & Co’s Januvia generating the most in sales in 2017, $5.1 and $3.7 billion, respectively. The majority of these top-selling anti-diabetics have already reached the peak of their sales, however, and are unlikely to continue to drive growth in the market. Instead, currently marketed drugs, Trulicity, Tresiba, Praluent, and Repatha are most likely to drive the growth of the metabolic disorders market in coming years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.